| Jayne Co. | |
|
4505 S Ocean Blvd 1002 Highland Beach FL 33487-4263 | |
| (561) 271-0153 | |
| Not Available |
| Full Name | Jayne Co. |
|---|---|
| Speciality | Clinic/center - Adolescent And Children Mental Health |
| Location | 4505 S Ocean Blvd, Highland Beach, Florida |
| Authorized Official Name and Position | Jayne N Levine (PRESIDENT) |
| Authorized Official Contact | 5612710153 |
| Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
| Mailing Address | Practice Location Address |
|---|---|
| Jayne Co. 4505 S Ocean Blvd 1002 Highland Beach FL 33487-4263 Ph: (561) 271-0153 | Jayne Co. 4505 S Ocean Blvd 1002 Highland Beach FL 33487-4263 Ph: (561) 271-0153 |
| NPI Number | 1073978250 |
|---|---|
| Provider Enumeration Date | 12/15/2015 |
| Last Update Date | 12/15/2015 |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073978250 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QM0850X | Clinic/center - Adult Mental Health | MH6838 (Florida) | Secondary |
| 261QM0855X | Clinic/center - Adolescent And Children Mental Health | MH6838 (Florida) | Primary |
News Archive
Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, has announced the availability of its new automation friendly anti-phospholipid assay format.
The Florida Senate on Wednesday unanimously approved a plan proposed by Gov. Charlie Crist (R) that aims to reduce the ranks of the state's 3.7 million uninsured residents, the Miami Herald reports (Caputo, Miami Herald, 4/17).
A new study by a researcher at the University of Montreal has looked at why people in relationships are unfaithful.
Scientists in London will be able to use and manipulate, in real-time, leading multi-million dollar scientific instruments and technology in the USA, following the official launch of the Global Lab at Imperial College London.
Patients benefitted from an important design element in the pivotal phase III clinical trial that led to Food and Drug Administration and worldwide regulatory approval of sunitinib for the treatment of gastrointestinal stromal tumors resistant to the only other available therapy, according to a study in Clinical Cancer Research, a journal of the American Association for Cancer Research.
› Verified 8 days ago